AMNIMO
23.3.2020 07:02:05 CET | Business Wire | Press release
amnimo Inc. (Headquarters: Musashino City, Tokyo; President & CEO: Koichi [Casey] Taniguchi; hereafter, “amnimo”) starts developing an industrial-use LTE gateway, “Edge Gateway,” which is equipped with rich computing resources and a high level of robustness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005056/en/
IoT is a mechanism by which a variety of devices are connected to each other via the network or the cloud service; these devices exchange information with each other. Recently, numerous approaches to the use of industrial-use IoT (IIoT) have been evolving in all types of industries. As IIoT continues to proliferate, examples of user work process improvements are increasing, but at the same time, we are witnessing operational issues such as suppressing failures in harsh external environments and being able to remotely deal with failures without going to the site. There have also been requests to process large volumes of data, such as video, using Edge in an advanced manner.
To resolve such issues, amnimo is developing the “Edge Gateway,” which is optimized for IIoT. The objective is to equip the Edge Gateway with LTE communication features that can be used in a wide variety of industries; in particular, to develop an optimal design for use in surveillance-camera systems.
[Characteristics of the Edge Gateway]
- Wide operating temperature range and power voltage range. Equipped with power circuits that are robust against noise and sudden outages, it has features for automatic recovery in case of a failure. This helps achieve stable operation even in harsh outdoor environments.
- Equipped with 2 GB of RAM and 32 GB eMMC for program storage space as the standard configuration, it can also be operated using a 2-TB SSD (Solid State Drive), enabling large-volume video data to be stored within the Edge Gateway.
- Equipped with a power-supply function for PoE(*1) compatible devices, it can be directly connected to a maximum of four IP cameras without using a PoE hub.
- The communication modules can accommodate two types of plastic SIM cards and eSIMs for a maximum of four different carrier SIMs, enabling the user to bypass communication failures by switching SIMs at high speeds in cases of emergency.
- Customer app development is possible on the Ubuntu OS; in addition, software development kits are provided for partners.
- Equipped with a VMS (Video Management System (*2)) as standard, simplifying the process of constructing small-, medium-, and large-scale surveillance systems.
- An extension port slot is internally provided in the Edge Gateway, enabling smooth addition of future functional extensions.
*1 Power over Ethernet: Specification wherein power is provided to the connected device(s) using Ethernet communication cables.
*2 System for saving and managing video captured using a surveillance camera.
In addition, we are developing a “device management system” to resolve issues related to operation on IIoT devices, such as the Edge Gateway. This device management system is a cloud service that enables initial configuration of IIoT devices, remote configuration and firmware updates, management of installation location, equipment life monitoring, log collection during operation, problem analysis and replacement, and transfer of configuration data for troubleshooting, thereby reducing the burden on the operator.
amnimo provides customer support for IIoT service and surveillance-camera systems, with the following objectives: “fast response and resolution for customer issues,” “value creation and innovation,” and “aim to grow with partners.”
About amnimo
amnimo was formed as a solely owned subsidiary of Yokogawa Electric Corporation as a new business to provide Industrial Internet of Things (IIoT) services in May 2018. With an excellent mobility, amnimo makes a swift decision and develops its business in a rapidly changing market. amnimo strengthens collaboration with customers and partner companies in various fields and countries to create new shared values by leveraging IIoT technologies.
To learn more, please visit https://amnimo.com/en/
The company names, organization names, and product names used in the document are registered trademarks or trademarks of the relevant organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom